Http://www.ngsmedicare.com/print.aspx?docid=21539

LCD for Nebulizers (L27226)
Contractor Information
Contractor Name
Contractor Number
Contractor Type
LCD Information
LCD ID Number
LCD Title
Contractor's Determination Number
AMA CPT / ADA CDT Copyright Statement
CPT codes, descriptions and other data only are copyright 2009 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors and other data contained therein) is copyright by the American Dental Association. 2002, 2004 American Dental Association. All rights reserved. Applicable FARS/DFARS apply. CMS National Coverage Policy
CMS Manual System, Pub. 100-3, Medicare National Coverage Determinations Manual, Chapter 1, Section 200.2, 280.1 Primary Geographic Jurisdiction
Illinois Indiana Kentucky Michigan Minnesota Ohio Wisconsin Oversight Region
http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 DME Region LCD Covers
Original Determination Effective Date
For services performed on or after 04/01/1997 Original Determination Ending Date
Revision Effective Date
For services performed on or after 01/01/2010 Revision Ending Date
Indications and Limitations of Coverage and/or Medical Necessity
For any item to be covered by Medicare, it must 1) be eligible for a defined Medicare benefit category, 2) be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member, and 3) meet all other applicable Medicare statutory and regulatory requirements. For the items addressed in this medical policy, the criteria for "reasonable and necessary" are defined by the following indications and limitations of coverage and/or medical necessity. For an item to be covered by Medicare, a written signed and dated order must be received by the supplier before a claim is submitted. If the supplier bills for an item addressed in this policy without first receiving the completed order, the item will be denied as not medically necessary. A small volume nebulizer (A7003, A7004, A7005), related compressor (E0570, E0571), and FDA-approved inhalation solutions of the drugs listed below are covered when: a. It is medically necessary to administer albuterol (J7611, J7613), arformoterol (J7605), budesonide (J7626), cromolyn (J7631), formoterol (J7606), ipratropium (J7644), levalbuterol (J7612, J7614), or metaproterenol (J7669) for the management of obstructive pulmonary disease (ICD-9 diagnosis codes 491.0–508.9) or b. It is medically necessary to administer dornase alpha (J7639) to a patient with cystic fibrosis (ICD-9 c. It is medically necessary to administer tobramycin (J7682) to a patient with cystic fibrosis or bronchiectasis (ICD-9 diagnosis code 277.02, 494.0, 494.1, 748.61, 011.50-011.56); or d. It is medically necessary to administer pentamidine (J2545) to a patient with HIV (ICD-9 diagnosis code 042), pneumocystosis (ICD-9 diagnosis code 136.3), or complications of organ transplants (ICD-9 diagnosis codes 996.80-996.89); or e. It is medically necessary to administer acetylcysteine (J7608) for persistent thick or tenacious pulmonary secretions (ICD-9 diagnosis codes 480.0-508.9, 786.4). Compounded inhalation solutions (J7604, J7607, J7609, J7610, J7615, J7622, J7624, J7627, J7628, J7629, J7632, J7634, J7635, J7636, J7637, J7638, J7640, J7641, J7642, J7643, J7645, J7647, J7650, J7657, J7660, J7667, J7670, J7676, J7680, J7681, J7683, J7684, J7685, and compounded solutions billed with J7699) will be denied as not medically necessary. If none of the drugs used with a nebulizer are covered, the compressor, the nebulizer, and other related accessories/supplies will be denied as not medically necessary. A large volume nebulizer (A7007, A7017), related compressor (E0565 or E0572), and water or saline (A4217 or A7018) are covered when it is medically necessary to deliver humidity to a patient with thick, tenacious http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 secretions, who has cystic fibrosis (ICD-9 diagnosis code 277.02), bronchiectasis (ICD-9 diagnosis code 494.0, 494.1, 011.50-011.56 or 748.61), a tracheostomy (ICD-9 diagnosis code V44.0 or V55.0), or a tracheobronchial stent (ICD-9 diagnosis code 519.19). Combination code E0585 will be covered for the same indications. An E0565 or E0572 compressor and filtered nebulizer (A7006) are also covered when it is medically necessary to administer pentamidine to patients with HIV (ICD-9 diagnosis code 042), pneumocystosis (ICD-9 diagnosis code 136.3) or complications of organ transplants (ICD-9 diagnosis codes 996.80-996.89). Because there is no proven medical benefit to nebulizing particles to diameters smaller than achievable with a pneumatic compressor, when a small volume ultrasonic nebulizer (E0574) is ordered to administer a covered inhalation solution, payment will be based on the allowance for the least costly medically appropriate alternative, a pneumatic compressor (E0570). Similarly, a large volume ultrasonic nebulizer (E0575) offers no proven clinical advantage over a pneumatic compressor. However, since code E0575 is in a different payment category than pneumatic compressors, payment for a least costly alternative cannot be made. Therefore, when an E0575 nebulizer is provided, it will be denied as not medically necessary as will any related accessories and supplies. A battery-powered compressor (E0571) is rarely medically necessary. If an E0571 compressor is provided and the coverage criteria for code E0570 are met, payment will be based on the allowance for the least costly medically appropriate alternative, E0570. A controlled dose inhalation drug delivery system (K0730) is covered when it is medically necessary to deliver the iloprost (Q4074) to patients with pulmonary artery hypertension (ICD-9 diagnosis codes 416.0 or 416.8) who meet the following criteria. Iloprost (Q4074) is covered when both criteria 1 and 2 are met: 1. The pulmonary hypertension is not secondary to pulmonary venous hypertension (e.g., left sided atrial or ventricular disease, left sided valvular heart disease, etc) or disorders of the respiratory system (e.g., chronic obstructive pulmonary disease, interstitial lung disease, obstructive sleep apnea or other sleep disordered breathing, alveolar hypoventilation disorders, etc.), and 2. The patient has primary pulmonary hypertension or pulmonary hypertension which is secondary to one of the following conditions: connective tissue disease, thromboembolic disease of the pulmonary arteries, human immunodeficiency virus (HIV) infection, cirrhosis, diet drugs, congenital left to right shunts, etc. If these conditions are present, the following criteria (a-d) must be met: a. The pulmonary hypertension has progressed despite maximal medical and/or surgical treatment b. The mean pulmonary artery pressure is greater than 25 mm Hg at rest or greater than 30 mm c. The patient has significant symptoms from the pulmonary hypertension (i.e., severe dyspnea on exertion, and either fatigability, angina, or syncope); and d. Treatment with oral calcium channel blocking agents has been tried and failed, or has been If the above criteria are not met the controlled dose inhalation drug delivery system (K0730) and the iloprost (Q4074) will be denied as not medically necessary. If K0730 is used to administer any other covered nebulizer drug other than iloprost and the coverage criteria for E0570 are met, payment will be based on the allowance for the least costly medically appropriate alternative, E0570. ACCESSORIES:
Accessories are separately payable if the related aerosol compressor and the individual accessories are medically necessary. The following table lists the compressor/generator, which is related to the accessories described. Other compressor/generator/accessory combinations are considered medically unnecessary. http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 COMPRESSOR/GENERATOR
RELATED ACCESSORIES
A4619, A7006, A7007, A7010, A7011, A7012, A7013, A7014, A7015, A7017, A7525, E1372 A7003, A7004, A7005, A7006, A7013, A7015, A7525 A7003, A7004, A7005, A7006, A7013, A7015, A7525 A4619, A7006, A7010, A7011, A7012, A7013, A7014, A7015, A7525 This array of accessories represents all possible combinations but it may not be appropriate to bill any or all of them for one device. The following table lists the usual maximum frequency of replacement for accessories. Claims for more than the usual maximum replacement amount will be denied as not medically necessary. ACCESSORY
USUAL MAXIMUM REPLACEMENT
The supplier must monitor the amount of supplies and accessories a patient is actually using and assure that the patient has nearly exhausted the supply on hand prior to dispensing any additional items. CMS’ Program Integrity Manual (Internet-Only Manual, CMS Pub. 100-8, Chapter 4, Section 4.26.1) requires, “Contact with the beneficiary or designee regarding refills should take place no sooner than approximately 7 days prior to the delivery/shipping date. For subsequent deliveries of refills, the supplier should deliver the DMEPOS product no sooner than approximately 5 days prior to the end of usage for the current product.” http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 INHALATION DRUGS AND SOLUTIONS:
The following table represents the maximum milligrams/month of inhalation drugs that are medically necessary for each nebulizer drug. INHALATION DRUGS AND S
MAXIMUM MILLIGRAMS/MONTH
OLUTIONS
930 micrograms per month – 62 units per month 1240 micrograms per month – 62 units per month 232.5 mg/month – 465 units/month (See below for exception) 2800 mg/month – 280 units per month (See below for exception) Sterile saline or water, 10ml/unit (A4216, A4218) Distilled water, sterile water, or sterile saline in large volume When albuterol, levalbuterol, or metaproterenol are prescribed as rescue/supplemental medication for patients who are taking formoterol or arformoterol, the maximum milligrams/month that are reasonably billed are: Claims for more than these amounts of drugs will be denied as not medically necessary. The pharmacist is responsible for assessing how much inhalation solution a patient is actually using. Considering this information, the pharmacist is responsible for assuring that the patient has used almost all of his/her supply on hand prior to dispensing a new supply. As referenced in the Program Integrity Manual (Internet-Only Manual, CMS Pub. 100-8, Chapter 4.26.1) “Contact with the beneficiary or designee regarding refills should take place no sooner than approximately 7 days prior to the delivery/shipping date. For subsequent deliveries of refills, the supplier should deliver the DMEPOS product no sooner than approximately 5 days prior to the end of usage for the current product.” When a "concentrated form" of an inhalation drug is covered, separate saline solution (A4216 or A4218 [metered dose]) used to dilute it will be separately reimbursed. Saline dispensed for the dilution of concentrated nebulizer drugs must be billed on the same claim as the drug(s) being diluted. If the unit dose form of the drug is dispensed, separate saline solution (A4216 or A4218 [metered dose]), will be denied as http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 not medically necessary. Water or saline in 500 or 1000 ml quantities (A4217 or A7018) are not appropriate for use by patients to dilute inhalation drugs and will therefore be denied as not medically necessary if used for this purpose. These codes are only medically necessary when used in a large volume nebulizer (A7007, A7017, or E0585). Albuterol, levalbuterol, and metaproterenol are all short-acting bronchodilators with beta-adrenergic stimulatory effect. It is not medically necessary for a patient to use more than one of these at a time. The use of more than one of these drugs at the same time will be denied as not medically necessary. Albuterol, levalbuterol, or metaproterenol is covered if it is used as a rescue/supplemental medication in addition to the long-acting beta-adrenergic agonist drug, formoterol or arformoterol. Formoterol and arformoterol are long-acting bronchodilators with beta-adrenergic stimulatory effect. It is not medically necessary for a patient to use more than one of these at a time. The use of more than one of these drugs at the same time will be denied as not medically necessary. Code J7620 describes the FDA-approved unit dose combination of albuterol base 2.5 mg and ipratropium bromide 0.5 mg in unit dose vials. The medical necessity for administering additional albuterol sulfate (J7611, J7613), levalbuterol (J7612, J7614) and/or ipratropium bromide (J7644) has not been established. Claims for J7611-J7614 and J7644 billed in addition to J7620 will be denied as not medically necessary. Charges for the drugs, diluent, and dispensing fees may only be billed by the entity that actually dispenses the drug to the Medicare beneficiary and that entity must be permitted under all applicable federal, state, and local laws and regulations to dispense drugs. Only entities licensed in the state where they are physically located may submit a claim for nebulizer drugs. Physicians may submit a claim for drugs if all of the following conditions are met: the physician is 1) enrolled as a DMEPOS supplier with the National Supplier Clearinghouse, and 2) dispensing the drug(s) to the Medicare beneficiary, and 3) authorized by the State to dispense drugs as part of the physician’s license. Claims submitted by entities not licensed to dispense drugs will be denied for lack of medical necessity. Coding Information
Bill Type Codes:
Contractors may specify Bill Types to help providers identify those Bill Types typically used to
report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that
Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type
and the policy should be assumed to apply equally to all claims.
Revenue Codes:
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically
used to report this service. In most instances Revenue Codes are purely advisory; unless specified
in the policy services reported under other Revenue Codes are equally subject to this coverage
determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by
Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.
CPT/HCPCS Codes
The appearance of a code in this section does not necessarily indicate coverage. EY - No physician or other licensed health care provider order for this item or service GA - Waiver of liability statement on file GZ - Item or service expected to be denied as not reasonable and necessary KO - Single drug unit dose formulation. KP - First drug of a multiple drug unit dose formulation. http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 KQ - Second or subsequent drug of a multiple drug unit dose formulation. KX - Requirements specified in the medical policy have been met HCPCS CODES:
EQUIPMENT
COMPRESSOR, AIR POWER SOURCE FOR EQUIPMENT WHICH IS NOT SELF- CONTAINED OR CYLINDER DRIVEN AEROSOL COMPRESSOR, BATTERY POWERED, FOR USE WITH SMALL VOLUME NEBULIZER AEROSOL COMPRESSOR, ADJUSTABLE PRESSURE, LIGHT DUTY FOR INTERMITTENT USE ULTRASONIC/ELECTRONIC AEROSOL GENERATOR WITH SMALL VOLUME NEBULIZER CONTROLLED DOSE INHALATION DRUG DELIVERY SYSTEM ACCESSORIES
ADMINISTRATION SET, WITH SMALL VOLUME NONFILTERED PNEUMATIC NEBULIZER, DISPOSABLE SMALL VOLUME NONFILTERED PNEUMATIC NEBULIZER, DISPOSABLE ADMINISTRATION SET, WITH SMALL VOLUME NONFILTERED PNEUMATIC NEBULIZER, NON-DISPOSABLE ADMINISTRATION SET, WITH SMALL VOLUME FILTERED PNEUMATIC NEBULIZER LARGE VOLUME NEBULIZER, DISPOSABLE, UNFILLED, USED WITH AEROSOL COMPRESSOR LARGE VOLUME NEBULIZER, DISPOSABLE, PREFILLED, USED WITH AEROSOL COMPRESSOR RESERVOIR BOTTLE, NON-DISPOSABLE, USED WITH LARGE VOLUME ULTRASONIC NEBULIZER CORRUGATED TUBING, DISPOSABLE, USED WITH LARGE VOLUME NEBULIZER, 100 FEET CORRUGATED TUBING, NON-DISPOSABLE, USED WITH LARGE VOLUME NEBULIZER, 10 FEET WATER COLLECTION DEVICE, USED WITH LARGE VOLUME NEBULIZER FILTER, DISPOSABLE, USED WITH AEROSOL COMPRESSOR FILTER, NONDISPOSABLE, USED WITH AEROSOL COMPRESSOR OR ULTRASONIC GENERATOR DOME AND MOUTHPIECE, USED WITH SMALL VOLUME ULTRASONIC NEBULIZER NEBULIZER, DURABLE, GLASS OR AUTOCLAVABLE PLASTIC, BOTTLE TYPE, NOT USED WITH OXYGEN NEBULIZER, DURABLE, GLASS OR AUTOCLAVABLE PLASTIC, BOTTLE TYPE, FOR USE WITH REGULATOR OR FLOWMETER INHALATION DRUGS
http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 STERILE WATER, SALINE AND/OR DEXTROSE, DILUENT/FLUSH, 10 ML STERILE SALINE OR WATER, METERED DOSE DISPENSER, 10 ML PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY PENTAMIDINE ISETHIONATE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER 300 MG ACETYLCYSTEINE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER GRAM ARFORMOTEROL, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, 15 MICROGRAMS FORMOTEROL FUMARATE, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, 20 MICROGRAMS LEVALBUTEROL, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, 0.5 MG ACETYLCYSTEINE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER GRAM ALBUTEROL, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE, 1 MG ALBUTEROL, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, 1 MG ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, CONCENTRATED FORM, 1 MG LEVALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, CONCENTRATED FORM, 0.5 MG ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE, 1 MG LEVALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE, 0.5 MG LEVALBUTEROL, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE, 0.5 MG ALBUTEROL, UP TO 2.5 MG AND IPRATROPIUM BROMIDE, UP TO 0.5 MG, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME BECLOMETHASONE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM BETAMETHASONE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM BUDESONIDE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, UP TO 0.5 MG BUDESONIDE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, UP TO 0.5 MG BITOLTEROL MESYLATE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, PER MILLIGRAM BITOLTEROL MESYLATE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM CROMOLYN SODIUM, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER 10 MILLIGRAMS http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 CROMOLYN SODIUM, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER 10 MILLIGRAMS BUDESONIDE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, PER 0.25 MILLIGRAM ATROPINE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, PER MILLIGRAM ATROPINE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM DEXAMETHASONE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, PER MILLIGRAM DEXAMETHASONE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM DORNASE ALFA, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM FORMOTEROL, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, 12 MICROGRAMS FLUNISOLIDE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE, PER MILLIGRAM GLYCOPYRROLATE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, PER MILLIGRAM GLYCOPYRROLATE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM IPRATROPIUM BROMIDE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM IPRATROPIUM BROMIDE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM ISOETHARINE HCL, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, PER MILLIGRAM ISOETHARINE HCL, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM ISOPROTERENOL HCL, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, PER MILLIGRAM ISOPROTERENOL HCL, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM METAPROTERENOL SULFATE, INHALATION SOLUTION, COMPOUNDED PRODUCT, CONCENTRATED FORM, PER 10 MILLIGRAMS METAPROTERENOL SULFATE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER 10 MILLIGRAMS METAPROTERENOL SULFATE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER 10 MILLIGRAMS PENTAMIDINE ISETHIONATE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER 300 MG TERBUTALINE SULFATE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, PER MILLIGRAM TERBUTALINE SULFATE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM TOBRAMYCIN, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, UNIT DOSE http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 FORM, ADMINISTERED THROUGH DME, PER 300 MILLIGRAMS TRIAMCINOLONE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, CONCENTRATED FORM, PER MILLIGRAM TRIAMCINOLONE, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER MILLIGRAM TOBRAMYCIN, INHALATION SOLUTION, COMPOUNDED PRODUCT, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER 300 MILLIGRAMS NOC DRUGS, INHALATION SOLUTION ADMINISTERED THROUGH DME PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); PER 30 DAYS PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); PER 90 DAYS ILOPROST, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, UP TO 20 MICROGRAMS ICD-9 Codes that Support Medical Necessity
The presence of an ICD-9 code listed in this section is not sufficient by itself to assure coverage. Refer to the section on “Indications and Limitations of Coverage and/or Medical Necessity” for other coverage criteria and payment information. For HCPCS codes A4619, E0565, E0572:
TUBERCULOUS BRONCHIECTASIS UNSPECIFIED EXAMINATION - TUBERCULOUS BRONCHIECTASIS TUBERCLE BACILLI NOT FOUND BY BACTERIOLOGICAL OR HISTOLOGICAL EXAMINATION BUT TUBERCULOSIS CONFIRMED BY OTHER METHODS (INOCULATION OF ANIMALS) HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE CYSTIC FIBROSIS WITH PULMONARY MANIFESTATIONS BRONCHIECTASIS WITHOUT ACUTE EXACERBATION COMPLICATIONS OF UNSPECIFIED TRANSPLANTED ORGAN - COMPLICATIONS OF OTHER SPECIFIED For HCPCS codes A7013, A7014, A7015, A7525:
TUBERCULOUS BRONCHIECTASIS UNSPECIFIED EXAMINATION - TUBERCULOUS BRONCHIECTASIS TUBERCLE BACILLI NOT FOUND BY BACTERIOLOGICAL OR HISTOLOGICAL EXAMINATION BUT TUBERCULOSIS CONFIRMED BY OTHER METHODS (INOCULATION OF ANIMALS) HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE CYSTIC FIBROSIS WITH PULMONARY MANIFESTATIONS PNEUMONIA DUE TO ADENOVIRUS - RESPIRATORY CONDITIONS DUE TO UNSPECIFIED EXTERNAL AGENT http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 COMPLICATIONS OF UNSPECIFIED TRANSPLANTED ORGAN - COMPLICATIONS OF OTHER SPECIFIED For HCPCS codes A7003, A7004, E0570, E0571, E0574:
TUBERCULOUS BRONCHIECTASIS UNSPECIFIED EXAMINATION - TUBERCULOUS BRONCHIECTASIS TUBERCLE BACILLI NOT FOUND BY BACTERIOLOGICAL OR HISTOLOGICAL EXAMINATION BUT TUBERCULOSIS CONFIRMED BY OTHER METHODS (INOCULATION OF ANIMALS) HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE CYSTIC FIBROSIS WITH PULMONARY MANIFESTATIONS PNEUMONIA DUE TO ADENOVIRUS - RESPIRATORY CONDITIONS DUE TO UNSPECIFIED EXTERNAL AGENT COMPLICATIONS OF UNSPECIFIED TRANSPLANTED ORGAN - COMPLICATIONS OF OTHER SPECIFIED For HCPCS codes A7006, J2545:
HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE COMPLICATIONS OF UNSPECIFIED TRANSPLANTED ORGAN - COMPLICATIONS OF OTHER SPECIFIED For HCPCS codes A4217, A7007, A7010, A7011, A7012, A7017, A7018, E0585, E1372:
TUBERCULOUS BRONCHIECTASIS UNSPECIFIED EXAMINATION - TUBERCULOUS BRONCHIECTASIS TUBERCLE BACILLI NOT FOUND BY BACTERIOLOGICAL OR HISTOLOGICAL EXAMINATION BUT TUBERCULOSIS CONFIRMED BY OTHER METHODS (INOCULATION OF ANIMALS) CYSTIC FIBROSIS WITH PULMONARY MANIFESTATIONS BRONCHIECTASIS WITHOUT ACUTE EXACERBATION http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 For HCPCS code A4216:
HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE SIMPLE CHRONIC BRONCHITIS - RESPIRATORY CONDITIONS DUE TO UNSPECIFIED EXTERNAL AGENT COMPLICATIONS OF UNSPECIFIED TRANSPLANTED ORGAN - COMPLICATIONS OF OTHER SPECIFIED For HCPCS codes J7608:
PNEUMONIA DUE TO ADENOVIRUS - RESPIRATORY CONDITIONS DUE TO UNSPECIFIED EXTERNAL For HCPCS codes J7605, J7606, J7611, J7612, J7613, J7614, J7620, J7626, J7631, J7644, J7669:
SIMPLE CHRONIC BRONCHITIS - RESPIRATORY CONDITIONS DUE TO UNSPECIFIED EXTERNAL AGENT For HCPCS code J7639:
CYSTIC FIBROSIS WITH PULMONARY MANIFESTATIONS For HCPCS code J7682:
TUBERCULOUS BRONCHIECTASIS UNSPECIFIED EXAMINATION - TUBERCULOUS BRONCHIECTASIS TUBERCLE BACILLI NOT FOUND BY BACTERIOLOGICAL OR HISTOLOGICAL EXAMINATION BUT TUBERCULOSIS CONFIRMED BY OTHER METHODS (INOCULATION OF ANIMALS) CYSTIC FIBROSIS WITH PULMONARY MANIFESTATIONS BRONCHIECTASIS WITHOUT ACUTE EXACERBATION For HCPCS codes K0730, Q4074
For HCPCS code A7005:
TUBERCULOUS BRONCHIECTASIS UNSPECIFIED EXAMINATION - TUBERCULOUS BRONCHIECTASIS TUBERCLE BACILLI NOT FOUND BY BACTERIOLOGICAL OR HISTOLOGICAL EXAMINATION BUT TUBERCULOSIS CONFIRMED BY OTHER METHODS (INOCULATION OF ANIMALS) HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE CYSTIC FIBROSIS WITH PULMONARY MANIFESTATIONS http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 PNEUMONIA DUE TO ADENOVIRUS - RESPIRATORY CONDITIONS DUE TO UNSPECIFIED EXTERNAL AGENT COMPLICATIONS OF UNSPECIFIED TRANSPLANTED ORGAN - COMPLICATIONS OF OTHER SPECIFIED Diagnoses that Support Medical Necessity
Refer to the previous section for the specific HCPCS code indicated. For all other HCPCS codes listed in the policy refer to the section on “Indications and Limitations of Coverage and/or Medical Necessity” for other criteria and payment information. ICD-9 Codes that DO NOT Support Medical Necessity
For the specific HCPCS codes indicated above, all ICD-9 codes that are not specified in the previous section. For HCPCS codes A7009, E0575, J7604, J7607, J7609, J7610, J7615, J7622, J7624, J7627, J7628, J7629, J7632, J7634, J7635, J7636, J7637, J7638, J7640, J7641, J7642, J7643, J7645, J7647, J7650, J7657, J7660, J7667, J7670, J7676, J7680, J7681, J7683, J7684, and J7685, all ICD-9 codes. For all other HCPCS codes, ICD-9 codes are not specified. ICD-9 Codes that DO NOT Support Medical Necessity Asterisk Explanation
Diagnoses that DO NOT Support Medical Necessity
For the specific HCPCS codes indicated above, all diagnoses that are not specified in the previous section. For HCPCS codes A7009, E0575, J7604, J7607, J7609, J7610, J7615, J7622, J7624, J7627, J7628, J7629, J7632, J7634, J7635, J7636, J7637, J7638, J7640, J7641, J7642, J7643, J7645, J7647, J7650, J7657, J7660, J7667, J7670, J7676, J7680, J7681, J7683, J7684, and J7685, all diagnoses. For all other HCPCS codes, diagnoses are not specified. General Information
Documentation Requirements
Section 1833(e) of the Social Security Act precludes payment to any provider of services unless "there has been furnished such information as may be necessary in order to determine the amounts due such provider." It is expected that the patient's medical records will reflect the need for the care provided. The patient's medical records include the physician's office records, hospital records, nursing home records, home health agency records, records from other healthcare professionals and test reports. This documentation must be available upon request. An order for each item billed must be signed and dated by the treating physician, kept on file by the supplier, and made available upon request. Items billed before a signed and dated order has been received by the supplier must be submitted with an EY modifier added to each affected HCPCS code. The order for any drug must clearly specify the type of solution to be dispensed to the patient and the administration instructions for that solution. The type of solution is described by a combination of (a) the name of the drug and the concentration of the drug in the dispensed solution and the volume of solution in each container, or (b) the name of the drug and the number of milligrams/grams of drug in the dispensed http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 solution and the volume of solution in that container. Examples of (a) would be: albuterol 0.083% 3 ml; or albuterol 0.5% 20 ml; or cromolyn 20 mg/2 ml. An example of (b) is: albuterol 1.25 mg in 3 ml saline. For compounded inhalation solutions, the order must include the following statement prior to signature by the physician: compounded inhalation solution – not FDA-approved. Administration instructions must specify the amount of solution and frequency of use. Examples would be: 3 ml qid and prn - max 6 doses/24 hr.; or one ampule q 4 hr prn; or 0.5 ml diluted with saline to 3.0 ml tid and prn. A new order is required if there is a change in the type of solution dispensed or the administration instructions. For all inhalation drugs, a new order is required at least every 12 months even if the prescription has not changed. An ICD-9 code describing the condition which necessitates nebulizer therapy must be included on each claim for equipment, accessories, and/or drugs. Suppliers must add a KX modifier to codes for K0730 and Q4074 only if all of the criteria in the Indications and Limitations of Coverage and/or Medical Necessity section of this policy have been met. If all of the criteria in the Indications and Limitations of Coverage and/or Medical Necessity section have not been met, the GA or GZ modifier must be added to the code. When there is an expectation of a medical necessity denial, suppliers must enter GA on the claim line if they have obtained a properly executed Advance Beneficiary Notice (ABN) or GZ if they have not obtained a valid ABN. Claim lines billed without a KX, GA, or GZ modifier will be rejected as missing information. When code E1399 is billed for miscellaneous equipment or accessories, the claim must be accompanied by a clear description of the item including the manufacturer and the model name/number if applicable. When Not Otherwise Classified (NOC) drug code J7699 is billed for miscellaneous inhalation drugs, the claim must be accompanied by the detailed order information described above and a clear statement of the number of ampules/bottles of solution dispensed. Refer to the Supplier Manual for more information on documentation requirements. Appendices
Utilization Guidelines
Refer to Indications and Limitations of Coverage and/or Medical Necessity. Sources of Information and Basis for Decision
Advisory Committee Meeting Notes
Start Date of Comment Period
End Date of Comment Period
Start Date of Notice Period
http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 Revision History Number
Revision History Explanation
Revision Effective Date: 01/01/2010
INDICATIONS AND LIMITATIONS OF COVERAGE:
Replaced: Q4080 with Q4074 in the Iloprost coverage indications
HCPCS CODES AND MODIFIERS:
Replaced: Q4080 with Q4074
ICD-9 CODES THAT SUPPPORT MEDICAL NECESSITY:
Replaced: Q4080 with Q4074 in the ICD-9 requirements
DOCUMENTATION REQUIREMENTS:
Replaced: Q4080 with Q4074 in the KX, GA and GZ modifiers requirements
Revision Effective Date: 12/01/2009
INDICATIONS AND LIMITATIONS OF COVERAGE:
Added: Language from Program Integrity Manual on timing of refills and shipping of supplies/medications
Revised: Coverage criteria for long-acting bronchodilators
HCPCS CODES AND MODIFIERS:
Added: GA and GZ modifiers
Revised: KX modifier descriptor
ICD-9 CODES THAT SUPPPORT MEDICAL NECESSITY:
Revised: ICD-9 codes for J7605, J7606
DOCUMENTATION REQUIREMENTS:
Deleted: KX requirements from J7605 & J7606
Added: Instructions for use of GA and GZ modifiers
08/08/2009 - This policy was updated by the ICD-9 2009-2010 Annual Update. Revision Effective Date: 01/01/2009
INDICATIONS AND LIMITATIONS OF COVERAGE:
Deleted: Least costly alternative statement for albuterol/ipratropium combination (J7620) scheduled to
become effective November 1, 2008.
Revised: Statement about denial of coverage when more than one beta-adrenergic agent is provided
Added: Maximum amount for albuterol/ipratropium combination
Added: Delivery timeframe for shipping of refills
HCPCS CODES:
Added: Code J7606 (formoterol fumarate)
Deleted: Code Q4099 (formoterol fumarate)
08/10/2008 - This policy was updated by the ICD-9 2008-2009 Annual Update. Revision Effective Date: 07/01/2008 unless otherwise noted (June 2008 Publication)
INDICATIONS AND LIMITATIONS OF COVERAGE:
Removed: Least costly alternative statement for levalbuterol
Revised: Effective date for implementation of least costly alternative statement for albuterol/ipratropium
combination (DuoNeb – J7620)
Removed: Bibliography references to levalbuterol
Revision Effective Date: 07/01/2008 (April Publication)
NATIONAL COVERAGE POLICY:
Added: NCD 200.2
INDICATIONS AND LIMITATIONS OF COVERAGE:
Substituted: J7611-J7614 for Q4093, Q4094
http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 Added: Q4099 as a new code for formoterol Added: Coverage criteria and maximum covered amount for formoterol. Added: J7604, J7632, and J7676 to the list of compounded drugs that are not covered. Added: Statement about denial if both formoterol and arformoterol are provided Added: Least costly alternative statement for levalbuterol. Added: Least costly alternative statement for unit dose combinations of albuterol and ipratropium. Revised: Coverage criteria for arformoterol. Revised: Statements concerning use of rescue medication to include use with formoterol. HCPCS CODES AND MODIFIERS: Added: J7604, J7605, J7632, J7676 (effective 1/1/08) Added: J7611, J7612, J7613, J7614, Q4099 (effective 4/1/08) Revised: J2545, J7608, J7631, J7639, Q4080 (effective 1/1/08) Deleted: Q4093, Q4094 (effective 1/1/08) (Note: Codes J7602 and J7603 were effective 1/1/08 – 3/31/08.) ICD-9 CODES THAT SUPPORT MEDICAL NECESSITY: Added: J7605, J7611-J7614,Q4099 Removed: Q4093, Q4094 Added: Covered diagnosis codes for formoterol. ICD-9 CODES/ DIAGNOSES THAT DO NOT SUPPORT MEDICAL NECESSITY: Added: J7604, J7632, J7676 DOCUMENTATION REQUIREMENTS: Added: Instructions for use of the KX modifier with Perforomist (formoterol). Revised: Instructions for use of the KX modifier with Brovana (arformoterol). SOURCES OF INFORMATION/ BASIS FOR DECISION: Added: Bibliography LCD ATTACHMENTS: Added: Response to Comments – April 2008 3/1/2008- In accordance with Section 911 of the Medicare Modernization Act, this policy was transitioned to DME MAC National Government Services (17003) LCD L27226 from DME PSC TriCenturion (77011) LCD L11499. Revision Effective Date : 07/01/2007 (June publication)
INDICATIONS AND LIMITATIONS OF COVERAGE:
Added coverage criteria and maximum covered amount for arformoterol.
Revised statement about J7699 to say that it will be denied when it is used to bill for a compounded inhalation
solution.
Added coverage statement and maximum covered amount for albuterol, levalbuterol, and metaproterenol
when used in addition to arformoterol.
Substituted code Q4093 and Q4094 for J7611-J7614.
HCPCS CODES:
Added: Q4093, Q4094
Deleted: J7611, J7612, J7613, J7614
ICD-9 CODES THAT SUPPORT MEDICAL NECESSITY:
Added: Q4093, Q4094
Deleted: J7611, J7612, J7613, J7614
Added covered diagnosis codes for arformoterol.
ICD-9 CODES/DIAGNOSES THAT DO NOT SUPPORT MEDICAL NECESSITY:
Removed J7699 from the list.
DOCUMENTATION REQUIREMENTS:
Added instructions for use of the KX modifier with arformoterol
Revision Effective Date : 07/01/2007 (March publication)
INDICATIONS AND LIMITATIONS OF COVERAGE:
Eliminated coverage for atropine, beclomethasone, betamethasone, bitolterol, dexamethasone, flunisolide,
glycopyrrolate, isoetharine, terbutaline, triamcinolone, and all other compounded inhalation solutions.
Changed ICD-9 code 519.1 to 519.19.
http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 Deleted the statement concerning providing information on a claim about the need for a portable compressor. Added utilization guideline for budesonide. HCPCS CODES AND MODIFIERS: (HCPCS code changes were effective 01/01/2007.) Added: J7607, J7609, J7610, J7615, J7634, J7640, J7645, J7647, J7650, J7657, J7660, J7667, J7670, J7685 Revised: J7611, J7612, J7613, J7614, J7620, J7622, J7624, J7626, J7627, J7628, J7629, J7635, J7636, J7637, J7638, J7640, J7641, J7642, J7643, J7644, J7669, J7680, J7681, J7682, J7683, J7684, Q4080 Removed: J7633, J7648, J7649, J7658, J7659, J7668 ICD-9 CODES THAT SUPPORT MEDICAL NECESSITY: Changed ICD-9 code 519.1 to 519.19. Added 416.0 and 416.8 to covered codes for A7005 Removed J7622, J7624, J7627, J7628, J7629, J7633, J7635, J7636, J7637, J7638, J7640, J7641, J7642, J7643, J7648, J7649, J7658, J7659, J7668, J7680, J7681, J7683, J7684 ICD-9 CODES AND DIAGNOSES THAT DO NOT SUPPORT MEDICAL NECESSITY: Added J7607, J7609, J7610, J7615, J7622, J7624, J7627, J7628, J7629, J7634, J7635, J7636, J7637, J7638, J7640, J7641, J7642, J7643, J7645, J7647, J7650, J7657, J7660, J7667, J7670, J7680, J7681, J7683, J7684, J7685, J7699 DOCUMENTATION REQUIREMENTS: Added a requirement for a specific statement on orders for compounded inhalation solutions. 06/01/2007 - In accordance with Section 911 of the Medicare Modernization Act of 2003, Virginia and West Virginia were transitioned from DME PSC TriCenturion (77011) to DME PSC TrustSolutions (77012). 03/01/2006 - In accordance with Section 911 of the Medicare Modernization Act of 2003, this policy was transitioned to DME PSC TriCenturion (77011) from DMERC Tricenturion (77011). Revision Effective Date 01/01/2006
INDICATIONS AND LIMITATIONS OF COVERAGE AND MEDICAL NECESSITY:
Inserted new HCPCS Codes A4216,A4218 and deleted codes J7051 and J7699 where appropriate.
Added coverage statement for code A7007.
Added A7007 to the related code table for E0565.
Added A7007 to usual maximum amount.
Added usual maximum amount for A4216 and A4218.
HCPCS CODES & MODIFIERS:
Added HCPCS codes A4218, G0333, J7620, J7627, Q0513, Q0514
Verbiage revision to description of HCPCS codes A4216, J7626
Deleted HCPCS codes J7051, J7616, G0371 and G0374.
ICD-9 CODES THAT SUPPORT MEDICAL NECESSITY:
Added J7620 and J7627 to the list of codes requiring ICD-9 code 491.0-508.9, deleted J7616.
Added A7007 to the 5th paragraph of HCPCS codes requiring specific ICD-9 codes.
Added A4216 and deleted A7051 from the 6th paragraph of HCPCS codes requiring specific ICD-9 codes.
DOCUMENTATION REQUIREMENTS:
Revised E1399 and J7699 documentation requirements.
Revision Effective Date: 10/01/2005
HCPCS CODES & MODIFIERS:
Added codes: K0730 and Q4080 and KX modifier
INDICATIONS AND LIMITATIONS OF COVERAGE AND/OR MEDICAL NECESSITY:
Added criterion for K0730 and Q4080
ICD-9 CODES THAT SUPPORT MEDICAL NECESSITY:
Added diagnoses codes 416.0, 416.8, necessary for codes K0730 and Q4080
DOCUMENTATION REQUIREMENTS:
Added KX modifier requirement for K0730 and Q4080.
Revision Effective Date: 04/01/2005
LMRP converted to LCD and Policy Article
HCPCS CODES & MODIFIERS:
Added Codes: J7611, J7612, J7613, J7614, J7616, G0371, G0374
http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 Deleted Codes: J7618, J7619, J7621, E0590 INDICATIONS AND LIMITATIONS OF MEDICAL NECESSITY: Tobramycin coverage expanded. Revision Effective Date: 04/01/2004
HCPCS CODES AND MODIFIERS:
Added: A4217, A7525, J7621
Deleted: A4621, A7019, A7020
INDICATIONS AND LIMITATIONS:
Added references to new HCPCS codes.
CODING GUIDELINES:
Added references to new HCPCS codes.
Clarified use of J7699.
Added billing guidelines for J7621.
Removed billing guidelines for A4323.
Added correct coding guidelines for compounded albuterol and ipratropium.
Added instructions for billing metered dose sterile saline products.
Revision effective date: 04/01/2003
HCPCS CODES AND MODIFIERS:
Added: EY modifier, J7633
Revised: E0574, J7626
INDICATIONS AND LIMITATIONS OF COVERAGE:
Added standard language concerning coverage of items without an order.
Added standard language concerning the medical necessity for use of a greater quantity and combinations of
usually contraindicated drugs requirement.
Removed language about physician documenting having considered use of an MDI prior to prescribing a
nebulizer. Added pneumocystosis and complications of organ transplants as coverage criteria for E0565 or
E0572 compressor used with filtered nebulizer (A7006).
Removed specific coverage criteria for dornase alpha, other than its being used for treatment of cystic fibrosis.
Removed grandfathering language for aerosol compressors and small and large volume ultrasonic generators.
CODING GUIDELINES:
Added: Instructions on how to bill J7626 0.5mg as one unit of service.
Added definitions of equipment and inhalations drugs to this section of policy.
DOCUMENTATION REQUIREMENTS:
Added: Standard language concerning use of EY modifier for items without an order; standard language
regarding excess quantity utilization;
Listed specific codes in which extra documentation should be attached to claim via hardcopy or narrative field
The revision dates listed below are the dates the revisions were published and not necessarily the effective dates for the revisions. 04/01/2002 - Expansion of coverage for large volume nebulizers with saline or water for use with Tracheobronchial stents (519.1). Expansion of indications for use of pentamidine with added ICD-9 codes. Expansion of indications for use of mucolytics with added ICD-9 codes. New HCPCS E codes replace K codes. New HCPCS codes for inhaled corticosteroids. Revision of HCPCS code for albuterol to include levalbuterol and its proper billing unit. 04/01/2000 – Several K codes crosswalked to A codes or J codes. Added “reasonable and necessary” language in Coverage and Payment Rules section. Revised all references of previous K codes. 06/01/1997 – Removed E0575 information in Documentation section. K0171 removed from covered codes for small volume nebulizer in Coverage and Payment Rules section. K0171 is not medically necessary for the administration of medications other than pentamidine. 03/01/1997 – Refer to article entitled “Nebulizer Policy Update” in the March 1997 DMERC Dialogue for a detailed report of the revision. http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539 Reason for Change
Last Reviewed On Date
Related Documents
Article(s)
A47233 - Nebulizers - Policy Article - Effective January 2010 LCD Attachments
http://www.ngsmedicare.com/PRINT.aspx?DOCID=21539

Source: http://www.ppsc.com/MedicareGuidelines/LCDs/Neb%20MCR%20B%20LCD%20L27226%2001.01.10.pdf